KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Operating Expenses: 2009-2025

Historic Operating Expenses for Jazz Pharmaceuticals (JAZZ) over the last 16 years, with Sep 2025 value amounting to $1.1 billion.

  • Jazz Pharmaceuticals' Operating Expenses rose 34.46% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $3.7 billion, marking a year-over-year increase of 11.07%. This contributed to the annual value of $3.4 billion for FY2024, which is 2.97% up from last year.
  • Latest data reveals that Jazz Pharmaceuticals reported Operating Expenses of $1.1 billion as of Q3 2025, which was up 12.04% from $953.7 million recorded in Q2 2025.
  • Over the past 5 years, Jazz Pharmaceuticals' Operating Expenses peaked at $1.2 billion during Q4 2022, and registered a low of $445.5 million during Q1 2021.
  • For the 3-year period, Jazz Pharmaceuticals' Operating Expenses averaged around $863.0 million, with its median value being $830.1 million (2024).
  • Over the last 5 years, Jazz Pharmaceuticals' Operating Expenses had its largest YoY gain of 125.47% in 2021, and its largest YoY loss of 38.51% in 2021.
  • Jazz Pharmaceuticals' Operating Expenses (Quarterly) stood at $847.4 million in 2021, then surged by 45.81% to $1.2 billion in 2022, then fell by 28.01% to $889.4 million in 2023, then rose by 0.90% to $897.4 million in 2024, then surged by 34.46% to $1.1 billion in 2025.
  • Its last three reported values are $1.1 billion in Q3 2025, $953.7 million for Q2 2025, and $897.4 million during Q4 2024.